Germany
Japan
United Kingdom
China
Products
Download
Lyve1 rabbit polyclonal antibody, Purified
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Mouse, Rat |
| Immunogen | Highly pure recombinant Mouse soluble LYVE-1 (Ala24-Gly228) produced in insect cells (Cat.-No DA3524). This recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis). |
Collagen I (COL1A1) rabbit polyclonal antibody, Biotin
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Bovine, Human, Mammalian, Mouse, Rat |
| Conjugation | Biotin |
| Immunogen | Collagen Type I from Human and Bovine placenta. |
Rabbit Polyclonal PD-L1 Antibody
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | PD-L1 antibody was raised against a 17 amino acid synthetic peptide from near the center of human PD-L1. The immunogen is located within amino acids 60 - 110 of PD-L1. |
LYVE1 rabbit polyclonal antibody, Aff - Purified
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Human |
| Immunogen | Highly pure recombinant Human soluble LYVE-1 produced in insect cells (Cat.-No DA3525). It consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). |
Lyve1 rabbit polyclonal antibody, Purified
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Mouse, Rat |
| Immunogen | Highly pure recombinant Mouse soluble LYVE-1 (Ala24-Gly228) produced in insect cells (Cat.-No DA3524). This recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis). |
Rabbit polyclonal HAPLN1 Antibody (N-term)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This HAPLN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 10-38 amino acids from the N-terminal region of human HAPLN1. |
Rabbit polyclonal HLA-G Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This HLA-G antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 62-89 amino acids from the Central region of human HLA-G. |
Rabbit Polyclonal Anti-Angiotensin II Receptor Type-1 (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide NSSTEDGIKRIQDDC, corresponding to amino acid residues 4-18 of human AT1 receptor. Extracellular, N-terminus. |
USD 524.00
In Stock
SMAD3 (417-425) pSer423/425 rabbit polyclonal antibody, Aff - Purified
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Bovine, Chicken, Human, Mouse, Porcine, Rat, Xenopus, Zebrafish |
| Immunogen | Synthetic peptide corresponding to amino acids 417-425 of Human SMAD3 protein. Epitope: pSer423/Ser425 |
Asialoganglioside GM1 rabbit polyclonal antibody, Ig Fraction
| Applications | Assay, CT, FC, FN, IHC, IP |
| Reactivities | Mouse, Rat |
| Immunogen | Asialo GM1 purified from Bovine brain tissue, methylated BSA and complete Freund's adjuvant. |
Rabbit Polyclonal Antibody against CD19 (N-term)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This CD19 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 143-172 amino acids from the N-terminal region of human CD19. |
LDL Receptor (LDLR) rabbit polyclonal antibody, Purified
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Immunogen | Specific synthetic peptide (sequence not conserved in VLDL receptor and LRP) of the LDL receptor extracellular domain. Epitope: Between residues Nos. 184-195, the linker region between repeats 4 and 5. |
Rabbit polyclonal ROR2 Antibody (N-term)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This ROR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 19-50 amino acids from the N-terminal region of human ROR2. |
Rabbit Polyclonal Anti-KV11.1 (HERG) (extracellular)
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide AFLLKETEEGPPATEC corresponding to residues 430-445 of human KV11.1 (HERG). Extracellular, between S1 and S2 domains. |
Rabbit polyclonal MGMT Antibody (C-term)
| Applications | FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This MGMT antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 156-182 amino acids from the C-terminal region of human MGMT. |
Rabbit Polyclonal Anti-Serotonin Transporter (SERT) (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide (C)EMRNEDVSEVAKD, corresponding to amino acids residues 388-400 of rat Serotonin Transporter. 4th extracellular loop. |
Rabbit polyclonal CP Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This CP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 547-577 amino acids from the Central region of human CP. |
Rabbit polyclonal CYP27B1 Antibody (C-term)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This CYP27B1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 482-508 amino acids from the C-terminal region of human CYP27B1. |
Rabbit Polyclonal Anti-Nectin-1 (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide (C)GKPPSVVSWETRLK, corresponding to amino acid residues 177- 190 of human nectin-1. Extracellular, N-terminus. |
Rabbit Polyclonal Anti-Cholecystokinin B Receptor (extracellular)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide CETPRIRGTGTRELE, corresponding to amino acid residues 39-53 of mouse Cholecystokinin B Receptor. Extracellular, N-terminus. |
USD 440.00
2 Weeks
Rabbit Polyclonal Antibody against NANOG (N-term)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This NANOG antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 15-49 amino acids from the N-terminal region of human NANOG. |
Rabbit Polyclonal 53BP1 Antibody
| Applications | FC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The epitope recognized by this antibody maps to a region between residues 350 and 400 of human 53BP1 [NP_005648.1 (GeneID 7158)]. |
Rabbit polyclonal ENOA Antibody (N-term)
| Applications | FC, IF, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This ENOA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 33-60 amino acids from the N-terminal region of human ENOA. |
Rabbit polyclonal GC Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This GC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 337-365 amino acids from the Central region of human GC. |
Rabbit Polyclonal CXCR4 Antibody
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | CXCR4 antibody was raised against a peptide corresponding to 14 amino acids near the amino terminus of human CXCR4. The immunogen is located within the first 50 amino acids of CXCR4. |
Active filters
Applications
- FC
Antibody Hosts
- Rabbit
Filter by
Target Symbol
- CD38 (7)
- CD3E (7)
- CD4 (6)
- EGFR (6)
- IL2RA (6)
- CD40 (5)
- CD40LG (5)
- TNFRSF17 (5)
- AKT1 (4)
- CASP3 (4)
- CD19 (4)
- CD22 (4)
- CD52 (4)
- CD8A (4)
- CEACAM1 (4)
- ERBB2 (4)
- IL3RA (4)
- S PROTEIN (4)
- SCARB1 (4)
- TLR7 (4)
- ALDH1A1 (3)
- AOC3 (3)
- BAD (3)
- C5AR1 (3)
- CD274 (3)
- CD28 (3)
- CD37 (3)
- CD74 (3)
- CD9 (3)
- CSF1R (3)
- DDIT3 (3)
- ENO1 (3)
- GYPA (3)
- HSPD1 (3)
- IL9 (3)
- KLF4 (3)
- MS4A4A (3)
- MYC (3)
- SELL (3)
- SLAMF7 (3)
- SMAD2 (3)
- STIP1 (3)
- SUMO1 (3)
- TMEM173 (3)
- UBB (3)
- ACKR3 (2)
- AGER (2)
- AKT2 (2)
- ALPL (2)
- APOL1 (2)
- C3AR1 (2)
- C7 (2)
- CALR (2)
- CASP5 (2)
- CCNG1 (2)
- CCNH (2)
- CCR2 (2)
- CCR5 (2)
- CCR7 (2)
- CCR8 (2)
- CCRL2 (2)
- CD14 (2)
- CD163 (2)
- CD27 (2)
- CD33 (2)
- CD44 (2)
- CD53 (2)
- CD63 (2)
- CD79B (2)
- CD80 (2)
- CD81 (2)
- CDC37 (2)
- CDH1 (2)
- CDH13 (2)
- CDKN2A (2)
- CNR2 (2)
- CP (2)
- CR1 (2)
- CR2 (2)
- CREB1 (2)
- CRHR2 (2)
- CTNNA1 (2)
- CTNNB1 (2)
- CTSK (2)
- CXCR1 (2)
- CXCR2 (2)
- CXCR4 (2)
- DAXX (2)
- DDAH1 (2)
- DDR1 (2)
- DDX11 (2)
- DTL (2)
- EGLN1 (2)
- EIF4EBP1 (2)
- ELF4 (2)
- EPCAM (2)
- ESAM (2)
- FADD (2)
- FADS2 (2)
- FAS (2)
Reactivities
- Human (853)
- Mouse (508)
- Rat (335)
- Bovine (65)
- Monkey (41)
- Pig (30)
- Chicken (29)
- Xenopus (14)
- Rabbit (13)
- Hamster (10)
- Zebrafish (7)
- Primate (6)
- Chimpanzee (5)
- Sheep (4)
- Cow (3)
- Dog (3)
- SARS-CoV-2 (3)
- Cynomolgus (2)
- Drosophila (2)
- Feline (2)
- Goat (2)
- Baboon (1)
- C. elegans (1)
- Canine (1)
- Dengue virus (1)
- Escherichia coli (1)
- Ferret (1)
- Fish (1)
- Guinea Pig (1)
- Macaque (1)
- Marmoset (1)
- Mustelid (1)
- Porcine (1)
- Rhesus Monkey (1)
- Staphylococcus aureus (1)
- Tree Shrew (1)
- West Nile Virus (1)
- Whale (1)
- Yellow Fever Virus (1)
Isotypes
Clonalities
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (55)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (34)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (18)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (13)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (9)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (6)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- Phospho-specific (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (1)
Assay Types
Families
- Druggable Genome (650)
- Transmembrane (350)
- Transcription Factors (142)
- Secreted Protein (126)
- ES Cell Differentiation/IPS (82)
- Protein Kinase (48)
- Stem cell - Pluripotency (48)
- GPCR (47)
- Protease (40)
- Embryonic stem cells (23)
- Adult stem cells (14)
- Induced pluripotent stem cells (14)
- Phosphatase (14)
- Cancer stem cells (11)
- Ion Channels: Other (8)
- Nuclear Hormone Receptor (8)
- Stem cell relevant signaling - JAK/STAT signaling pathway (8)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (6)
- P450 (5)
- Ion Channels: Cys-loop Receptors (4)
- Ion Channels: Potassium (4)
- Stem cell relevant signaling - Wnt Signaling pathway (4)
- Ion Channels: Sodium (2)
- Ion Channels: ATP Receptors (1)
- Ion Channels: Glutamate Receptors (1)
Pathways
- Metabolic pathways (116)
- Pathways in cancer (76)
- Cytokine-cytokine receptor interaction (42)
- MAPK signaling pathway (42)
- Neuroactive ligand-receptor interaction (39)
- Chemokine signaling pathway (30)
- Colorectal cancer (30)
- Focal adhesion (30)
- Alzheimer's disease (28)
- Huntington's disease (28)
- Prostate cancer (28)
- Hematopoietic cell lineage (27)
- Toll-like receptor signaling pathway (27)
- Cell adhesion molecules (CAMs) (26)
- Endometrial cancer (26)
- Insulin signaling pathway (26)
- Acute myeloid leukemia (25)
- T cell receptor signaling pathway (25)
- ErbB signaling pathway (24)
- Jak-STAT signaling pathway (24)
- Natural killer cell mediated cytotoxicity (24)
- Calcium signaling pathway (23)
- Chronic myeloid leukemia (23)
- Endocytosis (23)
- Regulation of actin cytoskeleton (23)
- Apoptosis (21)
- Melanogenesis (21)
- Melanoma (21)
- Pancreatic cancer (21)
- Wnt signaling pathway (21)
- Neurotrophin signaling pathway (20)
- Olfactory transduction (20)
- Fc epsilon RI signaling pathway (19)
- Non-small cell lung cancer (19)
- Renal cell carcinoma (19)
- Bladder cancer (18)
- Glioma (18)
- Progesterone-mediated oocyte maturation (18)
- VEGF signaling pathway (18)
- Adherens junction (17)
- Adipocytokine signaling pathway (17)
- B cell receptor signaling pathway (17)
- Complement and coagulation cascades (17)
- GnRH signaling pathway (17)
- Parkinson's disease (17)
- Purine metabolism (17)
- Tight junction (17)
- mTOR signaling pathway (17)
- Amyotrophic lateral sclerosis (ALS) (16)
- Leukocyte transendothelial migration (16)
- Antigen processing and presentation (15)
- Cell cycle (15)
- Small cell lung cancer (15)
- TGF-beta signaling pathway (15)
- Fc gamma R-mediated phagocytosis (14)
- p53 signaling pathway (14)
- Long-term depression (13)
- NOD-like receptor signaling pathway (13)
- Thyroid cancer (13)
- Vascular smooth muscle contraction (13)
- Drug metabolism - cytochrome P450 (12)
- Epithelial cell signaling in Helicobacter pylori infection (12)
- Glycolysis / Gluconeogenesis (12)
- Metabolism of xenobiotics by cytochrome P450 (12)
- Prion diseases (12)
- Systemic lupus erythematosus (12)
- Gap junction (11)
- Long-term potentiation (11)
- Pathogenic Escherichia coli infection (11)
- Viral myocarditis (11)
- Glutathione metabolism (10)
- Oocyte meiosis (10)
- Oxidative phosphorylation (10)
- PPAR signaling pathway (10)
- RNA degradation (10)
- Axon guidance (9)
- Fatty acid metabolism (9)
- Type I diabetes mellitus (9)
- Tyrosine metabolism (9)
- Allograft rejection (8)
- Cardiac muscle contraction (8)
- Glycerophospholipid metabolism (8)
- Primary immunodeficiency (8)
- RIG-I-like receptor signaling pathway (8)
- Ubiquitin mediated proteolysis (8)
- Valine (8)
- Arachidonic acid metabolism (7)
- Arginine and proline metabolism (7)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (7)
- Autoimmune thyroid disease (7)
- Dorso-ventral axis formation (7)
- Hypertrophic cardiomyopathy (HCM) (7)
- Retinol metabolism (7)
- Basal cell carcinoma (6)
- Biosynthesis of unsaturated fatty acids (6)
- ECM-receptor interaction (6)
- Lysosome (6)
- Notch signaling pathway (6)
- Phosphatidylinositol signaling system (6)
- Type II diabetes mellitus (6)
- leucine and isoleucine degradation (6)
- ABC transporters (5)
- Alanine (5)
- Aminoacyl-tRNA biosynthesis (5)
- Androgen and estrogen metabolism (5)
- Asthma (5)
- Cysteine and methionine metabolism (5)
- Dilated cardiomyopathy (5)
- Graft-versus-host disease (5)
- Hedgehog signaling pathway (5)
- Inositol phosphate metabolism (5)
- Nucleotide excision repair (5)
- O-Glycan biosynthesis (5)
- Porphyrin and chlorophyll metabolism (5)
- Pyrimidine metabolism (5)
- Renin-angiotensin system (5)
- Ribosome (5)
- Spliceosome (5)
- Taste transduction (5)
- Tryptophan metabolism (5)
- aspartate and glutamate metabolism (5)
- beta-Alanine metabolism (5)
- Base excision repair (4)
- Cytosolic DNA-sensing pathway (4)
- Drug metabolism - other enzymes (4)
- Ether lipid metabolism (4)
- Glycerolipid metabolism (4)
- Histidine metabolism (4)
- Lysine degradation (4)
- Phenylalanine metabolism (4)
- Propanoate metabolism (4)
- Sphingolipid metabolism (4)
- Starch and sucrose metabolism (4)
- alpha-Linolenic acid metabolism (4)
- Amino sugar and nucleotide sugar metabolism (3)
- Basal transcription factors (3)
- Butanoate metabolism (3)
- DNA replication (3)
- Glycosaminoglycan degradation (3)
- Glyoxylate and dicarboxylate metabolism (3)
- Heparan sulfate biosynthesis (3)
- Linoleic acid metabolism (3)
- Mismatch repair (3)
- Non-homologous end-joining (3)
- Other glycan degradation (3)
- Primary bile acid biosynthesis (3)
- Pyruvate metabolism (3)
- Regulation of autophagy (3)
- Citrate cycle (TCA cycle) (2)
- Fatty acid biosynthesis (2)
- Fatty acid elongation in mitochondria (2)
- Folate biosynthesis (2)
- Glycine (2)
- Glycosphingolipid biosynthesis - lacto and neolacto series (2)
- Homologous recombination (2)
- Limonene and pinene degradation (2)
- N-Glycan biosynthesis (2)
- Nitrogen metabolism (2)
- Pentose and glucuronate interconversions (2)
- Pentose phosphate pathway (2)
- Phenylalanine (2)
- RNA polymerase (2)
- Riboflavin metabolism (2)
- SNARE interactions in vesicular transport (2)
- Selenoamino acid metabolism (2)
- Steroid biosynthesis (2)
- leucine and isoleucine biosynthesis (2)
- serine and threonine metabolism (2)
- tyrosine and tryptophan biosynthesis (2)
- Ascorbate and aldarate metabolism (1)
- C21-Steroid hormone metabolism (1)
- Caffeine metabolism (1)
- Chondroitin sulfate biosynthesis (1)
- D-Glutamine and D-glutamate metabolism (1)
- Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (1)
- Keratan sulfate biosynthesis (1)
- Lysine biosynthesis (1)
- Maturity onset diabetes of the young (1)
- Methane metabolism (1)
- Nicotinate and nicotinamide metabolism (1)
- O-Mannosyl glycan biosynthesis (1)
- One carbon pool by folate (1)
- Protein export (1)
- Taurine and hypotaurine metabolism (1)
- Ubiquinone and other terpenoid-quinone biosynthesis (1)